Skip to main content
SpringerLink
Log in

Interfering with the production of cytokines in sepsis

  • Chapter
Book cover Cytokines in Severe Sepsis and Septic Shock

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

During septic shock the host produces several proinflammatory cytokines which have been implicated as playing a critical role in the pathogenesis of the disease. The cytokines which contribute to pathological changes in septic shock are not unique to infection. Multiple trauma, ischemia-reperfusion injury, acute transplant rejection, antigen-specific immune responses, and various acute inflammatory states (pancreatitis) initiate the same cytokine cascade and result in both systemic and local inflammatory processes. However, septic shock is a special case, since no other disease is associated with such high mortality, despite our ability to provide patients with appropriate antibiotics and supportive therapy. Gene deletion, neutralizing antibody studies, and specific receptor blockade of cytokines have been shown to have a pivotal role in the pathogenesis of septic shock, at least in animal studies. Normally, cytokine response is regulated by the intricate network of proinflammatory and anti-inflammatory mediators. The inflammatory response is kept in check by down-regulating production and counteracting the effects of cytokines already produced.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103: 565–575

    Article  CAS  PubMed  Google Scholar 

  2. Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269: 1829–1835

    Article  CAS  PubMed  Google Scholar 

  3. Bone RC, Grodzin CJ, Balk RA (1997) Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112: 235–243

    Article  CAS  PubMed  Google Scholar 

  4. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Trinchieri G, Karp CL (1997) Inhibition of human interleukin-12 production by pentoxifylline. Immunology 91: 197–203

    Article  CAS  PubMed  Google Scholar 

  5. Tracey KJ (1995) TNF and Mae West or: death from too much of a good thing [see comments]. Lancet 345: 75–76

    Article  CAS  PubMed  Google Scholar 

  6. Jansen PM, Boermeester MA, Fischer E, de Jong IW, Van der Poll T, Moldawer LL, Hack CE, Lowry SF (1995) Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1α administration and during lethal bacteremia. Blood 86: 1027–1034

    CAS  PubMed  Google Scholar 

  7. Smith JW, 2d, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC et al (1992) The toxic and hematologic effects of interleukin-1α administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 10: 1141–1152

    PubMed  Google Scholar 

  8. Parrat JR, Sturgess RM (1975) E. coli endotoxin shock in the cat: treatment with indomethacin. Brit J Pharmacol 33: 485–488

    Article  Google Scholar 

  9. Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome [see comments]. Ann Intern Med 119: 771–778

    CAS  PubMed  Google Scholar 

  10. Van der Poll T, Levi M, Hack CE, Ten Cate H, van Deventer SJ, Eerenberg AJ, de Groot ER, Jansen J, Gallati H, Buller HR et al (1994) Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 179: 1253–1259

    Article  PubMed  Google Scholar 

  11. Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11: 165–190

    Article  CAS  PubMed  Google Scholar 

  12. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA (1995) A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154: 5492–5499

    CAS  PubMed  Google Scholar 

  13. Vannier E, Miller LC, Dinarello CA (1992) Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 89: 4076–4080

    Article  CAS  PubMed  Google Scholar 

  14. Chantry D, Turner M, Abney E, Feldmann M (1989) Modulation of cytokine production by transforming growth factor-beta. J Immunol 142: 4295–4300

    CAS  PubMed  Google Scholar 

  15. Strieter RM, Remick DG, Ward PA, Spenger RN, Lynch JP, Larrick J, Kunkel SL (1988) Cellular and molecular regulation of tumor necrosis factor a production by pentoxifylline. Biochem Biophys Res Commun 155: 1230–1236

    Article  CAS  PubMed  Google Scholar 

  16. Semmler J, Gebert U, Eisenhut T, Moeller J, Schonharting MM, Allera A, Endres S (1993) Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 78: 520–525

    CAS  PubMed  Google Scholar 

  17. Giroir BP, Beutler B (1992) Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock 36: 200–207

    CAS  PubMed  Google Scholar 

  18. Endres S, Fülle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC (1991) Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor α and interleukin-1β by human mononuclear cells. Immunobiology 72: 56–60

    CAS  Google Scholar 

  19. Knudsen PJ, Dinarello CA, Strom TB (1986) Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 137: 3189–3193

    CAS  PubMed  Google Scholar 

  20. Ghezzi P, Dinarello CA (1988) Interleukin-1 induces interleukin 1. III. Specific inhibition of interleukin-1 production by gamma interferon. J Immunol 140: 4238–4242

    CAS  PubMed  Google Scholar 

  21. Scordamaglia A, Ciprandi G, Ruffoni S, Caria M, Paolieri F, Venuti D, Canonica GW (1988) Theophylline and the immune response: in vitro and in vivo effects. Clin Immunol Immunopathol 48: 238–245

    Article  CAS  PubMed  Google Scholar 

  22. Brandwein SR (1986) Regulation of interleukin-1 production by mouse peritoneal macrophages. Effects of arachidonic acid metabolites, cyclic nucleotides, and interferons. J Biol Chem 261: 8624–8630

    CAS  PubMed  Google Scholar 

  23. Tannenbaum CS, Hamilton TA (1989) Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 142: 1274–1280

    CAS  PubMed  Google Scholar 

  24. Zabel P, Wolter DT, Schonharting MM, Schade OF (1989) Oxpentifylline in endotoxaemia. Lancet 2: 1474–1477

    Article  CAS  PubMed  Google Scholar 

  25. Waage A, Sorensen M, Stordal B (1990) Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production [letter; comment]. Lancet 335: 543

    Article  CAS  PubMed  Google Scholar 

  26. Ward A, Clissold SP (1987) Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 34: 50–97

    Article  CAS  PubMed  Google Scholar 

  27. Rieneck K, Diamant M, Haahr PM, Schonharting M, Bendtzen K (1993) In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 37: 131–138

    Article  CAS  PubMed  Google Scholar 

  28. Zabel P, Schade OF (1993) Pentoxifylline as an anti-tumor necrosis factor alpha agent. Immunol Infect Dis 3: 175–180

    CAS  Google Scholar 

  29. Funk JO, Ernst M, Schönharting MM, Zabel P (1995) Pentoxifylline exerts synergistic immunomodulatory effects with dexamethasone or cyclosporine. Int J Immunopharmacol 17: 1007–1016

    Article  CAS  PubMed  Google Scholar 

  30. Thanhauser A, Reiling N, Bohle A, Toeliner KM, Duchrow M, Scheel D, Schluter C, Ernst M, Flad HD, Ulmer AJ (1993) Pentoxifylline: a potent inhibitor of IL-2 and IFNy biosynthesis and BCG-induced cytotoxicity. Immunology 80: 151–156

    CAS  PubMed  Google Scholar 

  31. Rott O, Cash E, Fleischer B (1993) Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 23: 1745–1751

    Article  CAS  PubMed  Google Scholar 

  32. Hussein A, Meyrick B, Graber S, Berry Lj, Brigham KL (1988) Attenuation of endotoxin-induced cytotoxicity and prostacyclin production in cultured bovine pulmonary artery endothelial cells by phosphodiesterase inhibition. Exp Lung Res 14: 637–654

    Article  CAS  PubMed  Google Scholar 

  33. Eigler A, Sinha B, Hartmann G, Endres S (1997) Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18: 487–492

    Article  CAS  PubMed  Google Scholar 

  34. Schade OF (1989) The role of prostacyclin in the protective effects of pentoxifylline and other xanthine derivatives in endotoxin action in mice. Eicosanoids 2: 183–188

    CAS  PubMed  Google Scholar 

  35. Rall TW (1982) Evolution of the mechanism of action of methylxanthines: from calci-um mobilizers to antagonists of adenosine receptors. Pharmacologist 24: 277–282

    Google Scholar 

  36. Han J, Thompson P, Beutler B (1990) Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172: 391–394

    Article  CAS  PubMed  Google Scholar 

  37. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 177: 1675–1680

    Article  CAS  PubMed  Google Scholar 

  38. Schade OF (1990) Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 31: 171–181

    CAS  PubMed  Google Scholar 

  39. Hadjiminas DJ, McMasters KM, Robertson SE, Cheadle WG (1994) Enhanced survival from cecal ligation and puncture with pentoxifylline is associated with altered neutrophil trafficking and reduced interleukin-1β expression but not inhibition of tumor necrosis factor synthesis. Surgery 116: 348–355

    CAS  PubMed  Google Scholar 

  40. Zabel P, Leimenstoll G, Schröder P, Elfeldt R, Schlaak M, Niedermayer W (1991) Pentoxifylline suppresses OKT3-induced tumor necrosis factor α formation in renal transplant recipients. Z Tx Med 3: 62–65

    Google Scholar 

  41. Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, Chiurco J, Kasdan P, Ahlers CM, Ecto LT et al (1993) Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group [see comments]. J Acquir Immune Defic Syndr 6: 787–794

    CAS  PubMed  Google Scholar 

  42. Dezube BJ, Sherman ML, Fridovich Keil JL, Allen Ryan J, Pardee AB (1993) Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 36: 57–60

    Article  CAS  PubMed  Google Scholar 

  43. Zabel P, Entzian P, Dalhoff K, Schlaak M (1997) Pentoxifylline in treatment of sarcoidosis. Am J Respi. Crit Care Med 155: 1665–1669

    CAS  Google Scholar 

  44. Zeni F, Pain P, Vindimian M, Gay JP, Gery P, Bertrand M, Page Y, Page D, Vermesch R, Bertrand JC (1996) Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 24: 207–214

    Article  CAS  PubMed  Google Scholar 

  45. Staubach KH, Schröder J, Stüber F, Gehrke K, Traumann E, Zabel P (1998) Effect of pentoxifylline in sepsis – results of a double-blind, randomized, placebo-controlled study. Arch Surg 133: 94–100

    Article  CAS  PubMed  Google Scholar 

  46. Hoffmann H, Markewitz A, Kreuzer E, Reichert K, Jochum M, Faist E (1998) Pentoxifylline decreases the incidence of multiple organ failure after major cardio-thoracic surgery. Shock 9: 235–240

    Article  CAS  PubMed  Google Scholar 

  47. Zabel P, Schade FU, Schlaak M (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187: 447–463

    Article  CAS  PubMed  Google Scholar 

  48. Gebert U, Okyayuz-Baklouti I, Thorwart W (1987) Tertiary hydroxyalkylxantines, procedure for their preparation, drugs containing them, and their use. Chem Abstr 106: 213–218

    Google Scholar 

  49. Hatherill JR, Yonemaru M, Zheng H, Hoffmann H, Fujishima S, Ishizaka A, Raffin TA (1989) Attenuation of acute lung injury in septic guinea-pigs by a new xanthine derivative (HWA-138). Pharmatherapeutica 5: 407–415

    CAS  PubMed  Google Scholar 

  50. Hoffmann H, Weiss M, Frank G, Birg A, Schönharting MM, Jochum M (1995) Amelioration of endotoxin-induced acute lung injury in pigs by HWA 138 and A 80 2715: new analogs of pentoxifylline. Shock 4: 166–170

    Article  CAS  PubMed  Google Scholar 

  51. Bahrami S, Redl H, Buurman WA, Schlag G (1992) Influence of the xanthine derivate HWA138 on endotoxin-related coagulation disturbances: effect in non-sensitized vs Dgalactosamine sensitized rats. Thromb Haemost 68: 418–423

    CAS  PubMed  Google Scholar 

  52. Bengtsson A, Redl H, Schlag G, Mollnes TE, Hogasen K (1996) Effect on complement activation and cytokine (TNFα and IL-8) release of infusion of anti-TNF-antibodies or a xanthine derivate (HWS 138) in septic baboons. Acta Anaesth Scand 40: 244–249

    Article  CAS  Google Scholar 

  53. Bahrami S, Yu Y-H, Redl H, Schlag G (1995) Acute lung injury by endotoxin-.induced mediators: prevention by HWA138, a new xanthine derivative. J Lab Clin Med 125: 487–492

    CAS  PubMed  Google Scholar 

  54. Boogaerts MA, Meeus P, Scheers W, Declercq M, Vande Broeck J, Verhoef G. (1990) Pentoxifylline and analogues: effects on normal and diseased granulocyte function in vitro. In: Hakim J, Mandell GL, Novick WJ (eds): Proceedings of the Workshop on Pentoxifylline and Analogues: Effects on leucocyte function. Sait Paul de Vece, France, 9–16

    Google Scholar 

  55. Bahrami S, Redl H, Schlag G, Leichtfried G, Ceska M, Strieter RM (1991) Comparison of the efficacy of different xanthine derivates to reduce endotoxin-induced mortality and/or cytokine production: in vivo and in vitro studies. Circ Shock 34: 140

    Google Scholar 

  56. Bahrami S, Yao Y-M, Shiga H, Leichtfried G, Redl H, Schlag G (1996) Comparison of the efficacy of pentoxifylline and albifyllin (HWA 138) on endotoxin-induced cytokine production, coagulation disturbances, and mortality. Shock 5: 424–428

    Article  CAS  PubMed  Google Scholar 

  57. Netea MG, Blok WL, Kullberg B-J, Bemelmans M, Vogels MTE, Buurman WA, van der Meer JWM (1995) Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 171: 393–399

    Article  CAS  PubMed  Google Scholar 

  58. Pahan K, Namboodiri AM, Sheikh FG, Smith BT, Singh I (1997) Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J Biol Chem 272: 7786–7791

    Article  CAS  PubMed  Google Scholar 

  59. Szabo C, Hasko G, Zingarelli B, Nemeth ZH, Salzman AL, Kvetan V, Pastores SM, Vizi ES (1997) Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivitiy in endotoxaemia. Immunology 90: 95–100

    Article  CAS  PubMed  Google Scholar 

  60. Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, Kobayashi J, Yamazaki F, Tanaka H, Inagaki N et al (1997) Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by β-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology 54: 144–152

    Article  CAS  PubMed  Google Scholar 

  61. Fortenberry JD, Huber AR, Owens ML (1997) Inotropes inhibit endothelial cell surface adhesion molecules induced by interleukin-1β. Crit Care Med 25: 303–308

    Article  CAS  PubMed  Google Scholar 

  62. Van der Poll T, Calvano SE, Kumar A, Coyle SM, Lowry SF (1997) Epinephrine attenuates down-regulation of monocyte tumor necrosis factor receptors during human endotoxemia. J Leukoc Biol 61: 156–160

    PubMed  Google Scholar 

  63. Spinas GA, Bloesch D, Keller U, Zimmerli W, Cammisuli S (1991) Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia. J Infect Dis 163: 89–95

    Article  CAS  PubMed  Google Scholar 

  64. Beyaert R, Cuenda A, Vanden-Berghe W, Plaisance S, Lee JC, Haegeman G, Cohen P, Fiers W (1996) The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 15: 1914–1923

    CAS  PubMed  Google Scholar 

  65. Granowitz EV, Clark BD, Vannier E, Callahan MV, Dinarello CA (1992) Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 79: 2356–2363

    CAS  PubMed  Google Scholar 

  66. Dinarello CA. (1996) Cytokines as mediators in the pathogenesis of septic shock. In: Rietschel ET Wagner H (eds): Pathology in septic shock. Springer-Verlag, Berlin, Heidelberg, 133–165

    Chapter  Google Scholar 

  67. Jorres A, Dinter H, Topley N, Gahl GM, Frei U, Scholz P (1997) Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine 9: 119–125

    Article  CAS  PubMed  Google Scholar 

  68. Fletcher JR, Ramwell PW (1980) Indomethacin improves survival after endotoxin in baboons. Adv Prostaglandin Thromboxan Leukot Res 7: 821–828

    CAS  Google Scholar 

  69. Haupt MT, Jastremski MS, Clemmer TP, Metz CA, Goris GB (1991) Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group [see comments]. Crit Care Med 19: 1339–1347

    Article  CAS  PubMed  Google Scholar 

  70. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD et al (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group [see comments]. N Engl J Med 336: 912–918

    Article  CAS  PubMed  Google Scholar 

  71. Schade UF, Burmeister I, Engel R (1987) Increased 13-hydroxyoctadecadienoic acid content in lipopolysaccharide stimulated macrophages. Biochem Biophys Res Commun 147: 695–700

    Article  CAS  PubMed  Google Scholar 

  72. Sirko SP, Schindler R, Doyle MJ, Weisman SM, Dinarello CA (1991) Transcription,translation and secretion of interleukin 1 and tumor necrosis factor: effects of tebufelone, a dual cyclooxygenase/5-lipoxygenase inhibitor. Eur.J Immunol 21: 243–250

    Article  CAS  PubMed  Google Scholar 

  73. Meydani SN, Dinarello CA (1993) Influence of dietary fatty acids on cytokine production and its clinical implications. Nutr Clin Pract 8: 65–72

    Article  CAS  PubMed  Google Scholar 

  74. Zon G (1995) Antisense phosphorothioate oligodeoxynucleotides: introductory con-cepts and possible molecular mechanisms of toxicity. Toxicol Lett 82–83: 419–424

    Article  CAS  PubMed  Google Scholar 

  75. Lefebvre dHellencourt C, Diaw L, Guenounou M (1995) Immunomodulation by cytokine antisense oligonucleotides. Eur Cytokine Netw 6: 7–19

    CAS  Google Scholar 

  76. Webber S, Zheng R, Kamal A, Withnall M, Karlsson JA (1997) IFNy production from human Th1 cells in controlled by Raf kinase. Int Arch Allergy Immunol 113: 275–278

    Article  CAS  PubMed  Google Scholar 

  77. Ding M, Zhang M, Wong JL, Voskuhl RR, Ellison GW (1996) Antisense blockade of inducible nitric oxide synthase in glial cells derived from adult SJL mice. Neurosci Lett 220: 89–92

    Article  CAS  PubMed  Google Scholar 

  78. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B (1997) Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vitro. Cancer Res 57: 3200–3207

    CAS  PubMed  Google Scholar 

  79. Ojwang JO, Mustain SD, Marshall HB, Rao TS, Chaudhary N, Walker DA, Hogan ME, Akiyama T, Revankar GR, Peyman A et al (1997) Modified antisense oligonucleotides directed against tumor necrosis factor receptor type I inhibit tumor necrosis factor α-mediated functions. Biochemistry 36: 6033–6045

    Article  CAS  PubMed  Google Scholar 

  80. Stein CA, Cheng Y-C (1993) Antisense oligonucleotides as therapeutic agents — is the bullet really magical? Science 261: 1004–1012

    Article  CAS  PubMed  Google Scholar 

  81. Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372: 333–335

    Article  CAS  PubMed  Google Scholar 

  82. Gibson I (1996) Antisense approaches to the gene therapy of cancer – ‘Recnac’. Cancer Metastasis Rev 15: 287–299

    Article  CAS  PubMed  Google Scholar 

  83. Knee R, Murphy RP (1997) Regulation of gene expression by natural antisense RNA transcripts. Neurochem Int 31: 379–392

    Article  CAS  PubMed  Google Scholar 

  84. Weiss B, Davidkova G, Zhang SP (1997) Antisense strategies in neurobiology. Neurochem Int 31: 321–348

    Article  CAS  PubMed  Google Scholar 

  85. Han J, Lee J-D, Bibbs L, Ulevitch RJ (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265: 808–811

    Article  CAS  PubMed  Google Scholar 

  86. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ (1996) MKK3- and MKK6regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 16: 1247–1255

    CAS  PubMed  Google Scholar 

  87. Nick JA, Avdi NJ, Gerwins P, Johnson GL, Worthen GS (1996) Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. J Immunol 156: 4867–4875

    CAS  PubMed  Google Scholar 

  88. Kramer RM, Roberts EF, Strifler BA, Johnstone EM (1995) Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem 270: 27395–27398

    Article  CAS  PubMed  Google Scholar 

  89. Kramer RM, Roberts EF, Hyslop PA, Utterback BG, Hui KY (1995) Differential activa-tion of cytosolic phospholipase A2 (cPLA2) by thrombin and thrombin receptor agonist peptide in human platelets. Evidence for activation of cPLA2 independent of the mitogen-activated protein kinases ERK1/2. J Biol Chem 270: 14816–14823

    Article  CAS  PubMed  Google Scholar 

  90. Lee JC, Laydon JT, McDonnell PC, Galagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW et al (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739–746

    Article  CAS  PubMed  Google Scholar 

  91. Pietersma A, Tilly BC, Gaestel M, de Jong N, Lee JC, Koster JF, Sluiter W (1997) p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. Biochem Biophys Res Commun 230: 44–48

    Article  CAS  PubMed  Google Scholar 

  92. Hennies HH, Günzler WA, Flohe L (1984) Influence of supimide on brain neurotransmitter systems of rats and mice. Arzneimittelforschung 34: 1471–1480

    CAS  PubMed  Google Scholar 

  93. Powell RJ (1996) New roles for thalidomide [editorial]. BMJ 313: 377–378

    Article  CAS  PubMed  Google Scholar 

  94. Postema PT, den Haan P, van Hagen PM, van Blankenstein M (1996) Treatment of col-itis in Behcet’s disease with thalidomide. Eur J Gastroenterol Hepatol 8: 929–931

    CAS  PubMed  Google Scholar 

  95. Gutierrez Rodriguez O, Starusta Bacal P, Gutierrez Montes O (1989) Treatment of refractory rheumatoid arthritis—the thalidomide experience. J Rheumatol 16: 158–163

    Google Scholar 

  96. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S (1995) Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32: 866–869

    Article  CAS  PubMed  Google Scholar 

  97. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR et al (1992) Thalidomide for the treatment of chronic graft-versus-host disease [see comments]. N Engl J Med 326: 1055–1058

    Article  CAS  PubMed  Google Scholar 

  98. Vogelsang GB, Hess AD, Gordon G, Brundrette R, Santos GW (1987) Thalidomide induction of bone marrow transplantation tolerance. Transplant Proc 19: 2658–2661

    CAS  PubMed  Google Scholar 

  99. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173: 699–703

    Article  CAS  PubMed  Google Scholar 

  100. McHugh SM, Rowland TL (1997) Thalidomide and derivatives: immunological investigations of tumor necrosis factor alpha (TNF) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 110: 151–154

    Article  CAS  PubMed  Google Scholar 

  101. Beauparlant P, Hiscott J (1996) Biological and biochemical inhibition of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev 7: 175–190

    Article  CAS  PubMed  Google Scholar 

  102. Rao A (1994) NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today 15: 274–281

    Article  CAS  PubMed  Google Scholar 

  103. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE (1996) Tumor necrosis factor a gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 16: 459–467

    CAS  PubMed  Google Scholar 

  104. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, Stirling DI (1996) Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 39: 3238–3240

    Article  CAS  PubMed  Google Scholar 

  105. Corral LG, Muller GW, Moreira AL et al (1996) Selection of noval analogs of thalidomide with enhanced tumor necrosis factor α inhibitory activity. Mol Med 2: 506–515

    CAS  PubMed  Google Scholar 

  106. Amano Y, Lee SW, Allison AC (1993) Inhibition by glucocorticoids of the formation of Peter Zabel and Soheyl Bahrami interleukin-lα, interleukin-1β, and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 43: 176–182

    CAS  PubMed  Google Scholar 

  107. Beato M (1989) Gene regulation by steroid hormones. Cell 56: 335–344

    Article  CAS  PubMed  Google Scholar 

  108. Rock CS, Coyle SM, Keogh CV, Lazarus DD, Hawes AS, Leskiw M, Moldawer LL, Stein TP, Lowry SF (1992) Influence of hypercortisolemia on the acute-phase protein response to endotoxin in humans. Surgery 112: 467–474

    CAS  PubMed  Google Scholar 

  109. Santos AA, Scheltinga MR, Lynch E, Brown EF, Lawton P, Chambers E, Browning J, Dinarello CA, Wolff SM, Wilmore DW (1993) Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg 128: 138–143

    Article  CAS  PubMed  Google Scholar 

  110. Fantuzzi G, Ghezzi P (1993) Glucocorticoids as cytokine inhibitors: role in neuroendocrine therapy of inflammatory diseases. Mediator Inflamm 2: 263–270

    Article  CAS  Google Scholar 

  111. Lefering R, Neugebauer EA (1995) Steroid controversy in sepsis and septic shock: a meta-analysis [see comments]. Crit Care Med 23: 1294–1303

    Article  CAS  PubMed  Google Scholar 

  112. Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE, Buchler M, Uhl W, Peter K (1994) Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Investig 72: 782–787

    Article  CAS  PubMed  Google Scholar 

  113. Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45–53

    Article  CAS  PubMed  Google Scholar 

  114. Robache-Gallea S, Morand V, Bruneau JM, Schoot B, Tagat E, Realo E, Chouaib S, Roman-Roman S (1995) In vitro processing of human tumor necrosis factor α. J Biol Chem 270: 23688–23692

    Article  CAS  PubMed  Google Scholar 

  115. Scuderi P (1989) Suppression of human leukocyte tumor necrosis factor secretion by the serine protease inhibitor p-toluenesulfonyl-L-arginine methyl ester (TAME). J Immunol 143: 168–173

    CAS  PubMed  Google Scholar 

  116. Niehorster M, Tiegs G, Schade UF, Wendel A (1990) In vivo evidence for protease-catalysed mechanism providing bioactive tumor necrosis factor alpha. Biochem Pharmacol 40: 1601–1603

    Article  CAS  PubMed  Google Scholar 

  117. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K et al (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 370: 218–220

    Article  CAS  PubMed  Google Scholar 

  118. McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S et al (1994) Regulation of tumour necrosis factor α processing by a metalloproteinase inhibitor. Nature 370: 558–561

    Article  CAS  PubMed  Google Scholar 

  119. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL et al (1994) Processing of tumour necrosis factor α precursor by metalloproteinases. Nature 370: 555–557

    Article  CAS  PubMed  Google Scholar 

  120. Gallea-Robache S, Morand V, Millet S, Bruneau JM, Bhatnagar N, Chouaib S, Roman-Roman S (1997) A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocyte cells. Cytokine 9: 340–346

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Forschungszentrum Borstel, Zentrum für Medizin und Biowissenschaften, Parkallee 35, D-23845, Borstel, Germany

    Peter Zabel

  2. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Donaueschingenstr. 13, A-1200, Vienna, Austria

    Soheyl Bahrami

Authors
  1. Peter Zabel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soheyl Bahrami
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Donaueschingenstrasse 13, A-1200, Vienna, Austria

    Heinz Redl  & Günther Schlag  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Basel AG

About this chapter

Cite this chapter

Zabel, P., Bahrami, S. (1999). Interfering with the production of cytokines in sepsis. In: Redl, H., Schlag, G. (eds) Cytokines in Severe Sepsis and Septic Shock. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8755-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8755-7_15

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9759-4

  • Online ISBN: 978-3-0348-8755-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation